NCT00081770View on ClinicalTrials.gov

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

PHASE3CompletedINTERVENTIONAL

Enrollment

4,469

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

1.5 ug/kg/week subcutaneously (SC) for 48 weeks

BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

1.0 ug/kg/week SC for 48 weeks

DRUG

REBETOL (ribavirin; SCH 18908)

weight based dose 800-1400 mg/day orally (PO) for 48 weeks

BIOLOGICAL

PEGASYS (peginterferon alfa-2a)

180 ug/week SC administered for 48 weeks

DRUG

COPEGUS (ribavirin)

1000-1200 mg/day PO for 48 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00081770 - Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) | Biotech Hunter | Biotech Hunter